Lawrence Russell Smith, VP, Vaccine Research at VICAL INC (VICL), sold 54 shares at $2.48 ($134) on 2017-01-11, disclosed to the SEC on 2017-01-13.
Scheduled sale ($134) by VP, Vaccine Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| VICL | SELL | 2016-10-12 | $165 | — | Filing → |
| VICL | SELL | 2016-07-13 | $241 | — | Filing → |
| VICL | SELL | 2016-03-17 | $4K | — | Filing → |